Friday, July 19, 2019 7:43:18 PM
Shorter's are relentless. Never thought I'd get caught again, but here I am. They can compete with good science vs their financial horsepower by picking a company with a need for capital to proceed with future phases. MRKR was made to order with a recently announced shelf offering followed by
PR. Their game plan is to pound the share price down, and they aren't done, to ty to force more selling and if they can, force it low enough to cause the company to increase the number of shares from the shelf offering to generate the funds needed. In a word, that's more dilution and with that, they will continue to pound it down.
These people don't care about cancer victims, cardiac patients, Alzheimer sufferers, etc. They will drive a company out of business if they can. Many of you are probably familiar with a company that had great promise in cancer treatment that closed today at 0.1235, has virtually no money and probably will never recover. Congratulations shortees.
That's what we are up against and good news tomorrow or Monday AM won't deter them.
Hopeful nevertheless.
PR. Their game plan is to pound the share price down, and they aren't done, to ty to force more selling and if they can, force it low enough to cause the company to increase the number of shares from the shelf offering to generate the funds needed. In a word, that's more dilution and with that, they will continue to pound it down.
These people don't care about cancer victims, cardiac patients, Alzheimer sufferers, etc. They will drive a company out of business if they can. Many of you are probably familiar with a company that had great promise in cancer treatment that closed today at 0.1235, has virtually no money and probably will never recover. Congratulations shortees.
That's what we are up against and good news tomorrow or Monday AM won't deter them.
Hopeful nevertheless.
Recent MRKR News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/20/2026 08:08:49 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/20/2026 08:07:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/20/2026 08:05:49 PM
- Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results • GlobeNewswire Inc. • 03/18/2026 09:31:30 PM
- Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/18/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 09:06:45 PM
- Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology • GlobeNewswire Inc. • 01/26/2026 12:00:00 PM
- Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer • GlobeNewswire Inc. • 01/05/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 09:10:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 09:01:15 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 11/17/2025 09:22:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 12:20:47 PM
- Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/14/2025 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 10:29:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/05/2025 12:36:59 PM
- Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors • GlobeNewswire Inc. • 11/05/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2025 10:09:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2025 10:03:27 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2025 09:54:39 PM
- Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting • GlobeNewswire Inc. • 11/03/2025 02:15:00 PM
- Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program • GlobeNewswire Inc. • 10/06/2025 11:30:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2025 11:30:37 AM
- Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference • GlobeNewswire Inc. • 08/28/2025 12:00:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2025 11:16:20 AM
